Pexmachina
5 employees on LinkedIn · 1 known investors
PexMachina develops physics-based molecular simulation for drug discovery, using quantum-ready computational chemistry and AI agents to predict properties like binding, stability, and oral availability of peptides. It delivers its PexAgent as an MCP service that integrates into LLM platforms such as Claude and Gemini, letting pharmaceutical researchers run molecular simulations via natural language within existing R&D workflows.
Founders & leadership
MK
Matthias KaiserinFounder
Investors · 1
Frequently asked questions
- What does Pexmachina do?
- PexMachina develops physics-based molecular simulation for drug discovery, using quantum-ready computational chemistry and AI agents to predict properties like binding, stability, and oral availability of peptides. It delivers its PexAgent as an MCP service that integrates into LLM platforms such as Claude and Gemini, letting pharmaceutical researchers run molecular simulations via natural language within existing R&D workflows.
- Who founded Pexmachina?
- Pexmachina was founded by Matthias Kaiser.
- Who are Pexmachina's investors?
- Pexmachina's investors include QAI Ventures.